Literature DB >> 27826923

Circulating MicroRNAs in Cancer.

Killian P O'Brien1, Eimear Ramphul1, Linda Howard2, William M Gallagher3, Carmel Malone1, Michael J Kerin1, Róisín M Dwyer4.   

Abstract

It is believed that microRNAs have potential as circulating biomarkers of disease; however, successful clinical implementation remains a challenge. This chapter highlights broad variations in approaches to microRNA analysis where whole blood, serum and plasma have each been employed as viable sources. Further discrepancies in approaches are seen in endogenous controls and extraction methods utilized. This has resulted in contradictory publications, even when the same microRNA is targeted in the same disease setting.Analysis of blood samples highlighted the impact of both collection method and storage, on the microRNA profile. Analysis of a panel of microRNAs across whole blood, serum, and plasma originating from the same individual emphasized the impact of starting material on microRNA profile. This is a highly topical field of research with immense potential for translation into the clinical setting. Standardization of sample harvesting, processing and analysis will be key to this translation. Methods of sample harvesting, preservation, and analysis are outlined, with important mitigating factors highlighted.

Entities:  

Keywords:  Breast Cancer; Circulating microRNAs; Plasma; Serum; Whole blood

Mesh:

Substances:

Year:  2017        PMID: 27826923     DOI: 10.1007/978-1-4939-6524-3_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  CMEP: a database for circulating microRNA expression profiling.

Authors:  Jian-Rong Li; Chun-Yip Tong; Tsai-Jung Sung; Ting-Yu Kang; Xianghong Jasmine Zhou; Chun-Chi Liu
Journal:  Bioinformatics       Date:  2019-09-01       Impact factor: 6.937

2.  Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma.

Authors:  Manjula Nakka; Wendy Allen-Rhoades; Yiting Li; Aaron J Kelly; Jianhe Shen; Aaron M Taylor; Donald A Barkauskas; Jason T Yustein; Irene L Andrulis; Jay S Wunder; Richard Gorlick; Paul S Meltzer; Ching C Lau; Tsz-Kwong Man
Journal:  Oncotarget       Date:  2017-05-27

Review 3.  Expression signatures and roles of MicroRNAs in human oesophageal adenocarcinomas.

Authors:  Xiangyi Kong; Shun Gong; Lijuan Su; Chen Li; Yanguo Kong
Journal:  J Cell Mol Med       Date:  2017-08-10       Impact factor: 5.310

Review 4.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

5.  CircLMTK2 acts as a novel tumor suppressor in gastric cancer.

Authors:  Jian He; Jie Chen; Ben Ma; Li Jiang; Guangfa Zhao
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

6.  MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.

Authors:  Flavia Biamonte; Gianluca Santamaria; Alessandro Sacco; Francesca Marta Perrone; Annalisa Di Cello; Anna Martina Battaglia; Alessandro Salatino; Anna Di Vito; Ilenia Aversa; Roberta Venturella; Fulvio Zullo; Francesco Costanzo
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

7.  Crosstalk between microRNAs, the putative target genes and the lncRNA network in metabolic diseases.

Authors:  Taís Silveira Assmann; Fermín I Milagro; José Alfredo Martínez
Journal:  Mol Med Rep       Date:  2019-08-21       Impact factor: 2.952

8.  Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer.

Authors:  Brian M Moloney; Katie E Gilligan; Doireann P Joyce; Clodagh P O'Neill; Killian P O'Brien; Sonja Khan; Claire L Glynn; Ronan M Waldron; Ciarán M Maguire; Emma Holian; Erin Naughton; Mohamed Elhadi; Andrea B Grealish; Carmel Malone; Emma McDermott; Peter Dockery; Thomas Ritter; Adriele Prina-Mello; Michael J Kerin; Róisín M Dwyer
Journal:  Cells       Date:  2020-01-07       Impact factor: 6.600

9.  Elevated miR-301a expression indicates a poor prognosis for breast cancer patients.

Authors:  Jin-Zhou Zheng; Yan-Ni Huang; Ling Yao; Yi-Rong Liu; Sheng Liu; Xin Hu; Zhe-Bin Liu; Zhi-Min Shao
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.